Compare Marvell Technology Inc (MRVL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs ResMed Inc. — how do they compare? Marvell Technology Inc trades at $271.47 (market cap $246.84B), while ResMed Inc. trades at $230.06 (market cap $31.89B). The key difference: Marvell Technology Inc is far larger — about 7.7× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and ResMed Inc. for 51 Days on average.
| MRVL | RMD | |
|---|---|---|
Market Cap | $246.84B | $31.89B |
Volume | 29,003,830 | 618,314 |
Sector | Technology | Health |
52-Week High | $316.43 | $277.88 |
52-Week Low | $73.73 | $182.82 |
Typical Hold Time | 42 Days | 51 Days |
Enterprise Value | $248.19B | $31.24B |
Dividend Yield | 0.09% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $271.49, down 4.63% today but maintains strong momentum with 210% year-to-date gains. The stock shows bullish technical signals with support at $267 and resistance at $282. Fundamentally, MRVL reported three consecutive earnings beats and projects explosive growth, with fiscal 2028 revenue guidance raised to $18 billion. Analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $327.86 consensus target.
MRVL presents compelling growth prospects driven by AI chip demand and hyperscaler partnerships, particularly the $120 billion Google deal. However, elevated valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) warrant caution. The stock's 210% surge this year increases volatility risk, though strong institutional support and custom silicon expansion provide long-term upside potential.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
